Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology

Defence Therapeutics Inc., a notable Canadian biopharmaceutical entity, has officially been granted a comprehensive U.S. patent for its innovative AccuTOX® technology, marking a substantial advancement in cancer treatment avenues. The United States Patent and Trademark Office (USPTO) issued patent no. 11,890,350, securing a wide range of therapeutically-active molecules integral to the AccuTOX® framework, potentially securing market exclusivity until late 2042.

The AccuTOX® platform utilizes specific bile acid-peptide conjugates that provoke cancer cell death through increased metabolic stress and the generation of reactive oxygen species. This technology has demonstrated potential in drastically reducing tumor volumes in various cancer types in studies. Furthermore, Defence's AccuTOX® has successfully undergone pre-clinical studies and acquired FDA approval for a Phase I clinical trial focusing on patients with advanced melanoma. This milestone underscores the pioneering role of AccuTOX® in developing next-generation antibody-drug conjugates (ADCs), offering a glimmer of hope for breakthrough cancer therapy solutions.

With this patent, Defence Therapeutics solidifies its commitment to exploring the commercial viability of AccuTOX® and enhancing its growing patent portfolio, which now includes four granted US patents. This development resonates with the company's pursuit of novel immune-oncology treatments, potentially transforming cancer patient care.